PMID- 26805660
OWN - NLM
STAT- MEDLINE
DCOM- 20160711
LR  - 20160229
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 117
IP  - 6
DP  - 2016 Mar 15
TI  - Usefulness of Plasma Matrix Metalloproteinase-3 Levels to Predict Myocardial 
      Infarction in Men With and Without Acute Coronary Syndrome.
PG  - 881-6
LID - S0002-9149(15)30040-0 [pii]
LID - 10.1016/j.amjcard.2015.12.022 [doi]
AB  - Matrix metalloproteinase-3 (MMP-3), or stromelysin-1, is a matrix 
      metalloproteinase which is expressed in atherosclerotic plaques and which has 
      been implicated in the pathogenesis of acute coronary syndrome (ACS). Functional 
      polymorphisms in the promoter region of the human MMP-3 gene resulting in an 
      increased expression of MMP-3 have been shown to predict the risk of incident 
      myocardial infarction (MI). However, there have been no studies that have 
      specifically examined the utility of baseline plasma MMP-3 levels for the 
      prediction of long-term MI. In this study, baseline plasma MMP-3 levels were 
      measured in 355 male patients who were referred for coronary angiography and 
      followed prospectively for the development of enzymatically confirmed MI out to 
      5 years. After adjustment for a variety of baseline clinical, angiographic, and 
      laboratory parameters, plasma MMP-3 levels were an independent predictor of MI at 
      5 years (hazards ratio 1.42, 95% CI 1.13 to 1.79; p = 0.0023). Furthermore, in 5 
      additional multivariate models that included a variety of contemporary biomarkers 
      associated with adverse outcomes and MI, MMP-3 remained an independent predictor 
      of MI at 5 years. Similar results were obtained when the analyses were restricted 
      to the subpopulation of patients presenting with ACS. In conclusion, elevated 
      levels of MMP-3 are associated with an increased risk of long-term MI in patients 
      with and without ACS referred for coronary angiography. Furthermore, this 
      association is independent of a variety of clinical, angiographic, laboratory 
      variables, including biomarkers with established prognostic efficacy for the 
      prediction of MI.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Cavusoglu, Erdal
AU  - Cavusoglu E
AD  - Division of Cardiology, Department of Medicine, Bronx Veterans Affairs Medical 
      Center, Bronx, New York; Division of Cardiology, Department of Medicine, State 
      University of New York Downstate Medical Center, Brooklyn, New York. Electronic 
      address: ECavusoglu@aol.com.
FAU - Marmur, Jonathan D
AU  - Marmur JD
AD  - Division of Cardiology, Department of Medicine, State University of New York 
      Downstate Medical Center, Brooklyn, New York.
FAU - Kassotis, John T
AU  - Kassotis JT
AD  - Division of Cardiology, Department of Medicine, State University of New York 
      Downstate Medical Center, Brooklyn, New York.
FAU - Yanamadala, Sunitha
AU  - Yanamadala S
AD  - Division of Cardiology, Department of Medicine, State University of New York 
      Downstate Medical Center, Brooklyn, New York.
FAU - Chopra, Vineet
AU  - Chopra V
AD  - Division of Cardiology, Department of Medicine, Bronx Veterans Affairs Medical 
      Center, Bronx, New York.
FAU - Eng, Calvin
AU  - Eng C
AD  - Division of Cardiology, Department of Medicine, Bronx Veterans Affairs Medical 
      Center, Bronx, New York.
LA  - eng
PT  - Journal Article
DEP - 20151229
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Acute Coronary Syndrome/*blood/diagnosis/mortality
MH  - Aged
MH  - Biomarkers/blood
MH  - Coronary Angiography
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Myocardial Infarction/*blood/*diagnosis/mortality
MH  - Polymorphism, Genetic
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Time Factors
MH  - Veterans
EDAT- 2016/01/26 06:00
MHDA- 2016/07/12 06:00
CRDT- 2016/01/26 06:00
PHST- 2015/09/09 00:00 [received]
PHST- 2015/12/16 00:00 [revised]
PHST- 2015/12/16 00:00 [accepted]
PHST- 2016/01/26 06:00 [entrez]
PHST- 2016/01/26 06:00 [pubmed]
PHST- 2016/07/12 06:00 [medline]
AID - S0002-9149(15)30040-0 [pii]
AID - 10.1016/j.amjcard.2015.12.022 [doi]
PST - ppublish
SO  - Am J Cardiol. 2016 Mar 15;117(6):881-6. doi: 10.1016/j.amjcard.2015.12.022. Epub 
      2015 Dec 29.